Company intelligence / Profile preview

EverZom

Paris, Ile-de-France, Franceeverzom.com ↗

Ownership: Private
Development stage: Preclinical

Overview

EVerZom’s lead candidate, EVerGel—a combination of exosomes with a hydrogel biomaterial—has shown highly promising preclinical results in a porcine model of complex perianal fistulas associated with Crohn’s disease. Complete healing was achieved in 87.5% of treated cases versus only 12.5% in controls after four weeks. Clinical trials are targeted to begin as early as 2026; commercialization could occur by around 2030 if successful.

Therapeutic areas: GastroenterologyNeurologyOther
Modalities: Exosome-based therapyHydrogel-based drug delivery therapyBiologic
Industry: Biotech

Drug pipeline

1 asset

EVerGel

Preclinical

Partnerships

Around twenty global partnerships across human health, animal health, and cosmetics sectors; specific partners not named publicly as of June 2025

Beyond the preview

Go deeper on EverZom.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EverZom.

Explore the full profile